These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 1631793

  • 1. Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
    Nelles L, Li XK, Vanlinthout I, De Cock F, Lijnen HR, Collen D.
    Thromb Haemost; 1992 Apr 02; 67(4):445-52. PubMed ID: 1631793
    [Abstract] [Full Text] [Related]

  • 2. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
    Lijnen HR, Webb PD, Van Hoef B, De Cock F, Stassen JM, Prior SD, Collen D.
    Thromb Haemost; 1992 Feb 03; 67(2):239-47. PubMed ID: 1621244
    [Abstract] [Full Text] [Related]

  • 3. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D.
    Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163
    [Abstract] [Full Text] [Related]

  • 4. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L, Lijnen HR, Van Nuffelen A, Demarsin E, Collen D.
    Thromb Haemost; 1990 Aug 13; 64(1):53-60. PubMed ID: 2148847
    [Abstract] [Full Text] [Related]

  • 5. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
    Li XK, Lijnen HR, Nelles L, Van Hoef B, Stassen JM, Collen D.
    Blood; 1992 Jan 15; 79(2):417-29. PubMed ID: 1730087
    [Abstract] [Full Text] [Related]

  • 6. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
    Collen D, Lijnen HR, Vanlinthout I, Kieckens L, Nelles L, Stassen JM.
    Thromb Haemost; 1991 Feb 12; 65(2):174-80. PubMed ID: 1905070
    [Abstract] [Full Text] [Related]

  • 7. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the finger domain.
    Yahara H, Matsumoto K, Maruyama H, Nagaoka T, Ikenaka Y, Yajima K, Fukao H, Ueshima S, Matsuo O.
    Thromb Haemost; 1992 Dec 07; 68(6):672-7. PubMed ID: 1287881
    [Abstract] [Full Text] [Related]

  • 8. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 9. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
    Collen D, Lijnen HR, Bulens F, Vandamme AM, Tulinsky A, Nelles L.
    J Biol Chem; 1990 Jul 25; 265(21):12184-91. PubMed ID: 2115513
    [Abstract] [Full Text] [Related]

  • 10. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK.
    Thromb Haemost; 1994 Jul 25; 72(1):98-104. PubMed ID: 7974384
    [Abstract] [Full Text] [Related]

  • 11. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T, Iwasa S, Kakinuma A, Stassen JM, Lijnen HR, Collen D.
    Thromb Haemost; 1991 Dec 02; 66(6):684-93. PubMed ID: 1796414
    [Abstract] [Full Text] [Related]

  • 12. Characterization of human tissue-type plasminogen activator variants with amino acid mutations in the kringle 1 domain.
    Ikenaka Y, Yajima K, Yahara H, Maruyama H, Matsumoto K, Okada K, Ueshima S, Matsuo O.
    Blood Coagul Fibrinolysis; 1992 Aug 02; 3(4):381-7. PubMed ID: 1330023
    [Abstract] [Full Text] [Related]

  • 13. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N.
    Thromb Haemost; 1997 Apr 02; 77(4):725-9. PubMed ID: 9134650
    [Abstract] [Full Text] [Related]

  • 14. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
    Lijnen HR, Nelles L, Van Hoef B, De Cock F, Collen D.
    J Biol Chem; 1990 Apr 05; 265(10):5677-83. PubMed ID: 2156824
    [Abstract] [Full Text] [Related]

  • 15. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M, Cavallo LG, Agnelli G, Mele A, Bürgi R, Heim J, Semeraro N.
    Thromb Haemost; 1993 May 03; 69(5):466-72. PubMed ID: 8391727
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fibrin-specific thrombolytic agents.
    Collen D.
    Klin Wochenschr; 1988 May 03; 66 Suppl 12():15-23. PubMed ID: 3126344
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.